# Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Source: https://onco.cc/trials/nct04291105/  
OnCo record `nct04291105` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cemiplimab in melanoma and head and neck squamous cell carcinoma, run by Vyriad, Inc., active and no longer recruiting.

## Summary

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is a phase 2 interventional study registered as NCT04291105 by Vyriad, Inc., with 87 participants planned, started 2020-04-24 and due to reach its primary completion in 2026-10. Interventions recorded: VV1, Cemiplimab. Conditions listed: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04291105
- Phase: 2
- Setting: Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors
- Sponsor: Vyriad, Inc.
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT04291105: https://clinicaltrials.gov/study/NCT04291105

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Vyriad](https://onco.cc/companies/vyriad/)

---
JSON: https://onco.cc/api/v1/entities/nct04291105.json